Skip to Content

New Drug Approvals Archive - June 2015

June 2015

Kengreal (cangrelor) for Injection

Date of Approval: June 22, 2015
Company: The Medicines Company
Treatment for: Percutaneous Coronary Intervention

Kengreal (cangrelor) is an intravenous P2Y12 platelet inhibitor indicated for use in patients undergoing Percutaneous Coronary Intervention (PCI) to reduce the risk of periprocedural thrombotic events.

Read more: Kengreal (cangrelor) FDA Approval History

Tuxarin ER (chlorpheniramine and codeine)

Date of Approval: June 22, 2015
Company: Spriaso LLC
Treatment for: Cough, Cold Symptoms

Tuxarin ER (codeine and chlorpheniramine) is a long acting narcotic antitussive and antihistamine combination for the treatment of cough and cold symptoms.

Read more: Tuxarin ER (chlorpheniramine and codeine) FDA Approval History

New Drug Approvals Archive